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Abstract
To develop transgenic lines for conditional expression of desired genes in rats, we generated
several lines of the transgenic rats carrying the tetracycline-controlled transactivator (tTA)
gene. Using a vigorous, ubiquitous promoter to drive the tTA transgene, we obtained
widespread expression of tTA in various tissues. Expression of tTA was sufficient to strongly
activate its reporter gene, but was below the toxicity threshold. We examined the dynamics
of Doxycycline (Dox)-regulated gene expression in transgenic rats. In the two transmittable
lines, tTA-mediated activation of the reporter gene was fully subject to regulation by Dox.
Dox dose-dependently suppressed tTA-activated gene expression. The washout time for the
effects of Dox was dose-dependent. We tested a complex regime of Dox administration to
determine the optimal effectiveness and washout duration. Dox was administered at a high
dose (500 μg/ml in drinking water) for two days to reach the effective concentration, and
then was given at a low dose (20 μg/ml) to maintain effectiveness. This regimen of Dox administration can achieve a quick switch between ON and OFF statuses of tTA-activated gene
expression. In addition, administration of Dox to pregnant rats fully suppressed postnatal
tTA-activated gene expression in their offspring. Sufficient levels of Dox are present in
mother’s milk to produce maximal efficacy in nursing neonates. Administration of Dox to
pregnant or nursing rats can provide a continual suppression of tTA-dependent gene expression during embryonic and postnatal development. The tTA transgenic rat allows for
inducible and reversible gene expression in the rat; this important tool will be valuable in the
development of genetic rat models of human diseases.
Key words: Rats; transgenic; tetracycline-controlled transactivator; tTA; Doxycycline; Leucine Rich
Repeat Kinase 2; LRRK2

1. Introduction
Rodents are an ideal laboratory animal model for
functional genetic studies, because breeding cycles are
short and because methods of gene manipulation
have been developed in laboratory mice and rats [1-5].
Compared to mice, rats have a longer history of use in

physiological and pharmacologic studies [6, 7].
Therefore, a wealth of experimental data on rats can
be supplemented with genetic analysis [1]. Rats show
advantage over mice in the ease of microsurgery [8, 9],
in multiple sampling, and in behavior analyses. Adhttp://www.biolsci.org
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ditionally, the rats are more affordable for breeding
than larger mammalian animals [1, 6, 7]. However,
mice have been preferred by geneticists for decades
because totipotent embryonic stem (ES) cells have
been initially developed in mice rather than in other
mammalian animals [10]. The situation is going to
change as totipotent ES cells are developed in rats [11,
12]. Moreover, a need for transgenic rats has been
pursued because rats often serve as a superior model
of human disease, compared to mice [1, 2, 6, 7, 13].
Rats often recapitulate human disease phenotypes more accurately than the mice, as exemplified
by rats transgenic for the rennin-2 gene, the cholesterylester transfer gene, or the huntingtin gene [14-16].
Rats model type 1 diabetes better than mice in both
the pathogenesis of disease and the response to
treatment. As suggested by epidemiological studies,
type 1 diabetes is caused by non-genetic environmental factors that operate in a genetically susceptible
host to initiate a destructive immune process. A viral
infection readily induces diabetes in several rat models [17], but fails to induce diabetes in mice [18].
Clinical studies suggest that neither parenteral nor
oral insulin can prevent or delay diabetes onset in
human patients [19]. Both parenteral and oral administration of insulin prevents diabetes in mouse
models [20], but fail to do so in rats. Data from the rat
model, but not the mouse model, of diabetes is consistent with clinical studies. Such differences may be
caused by species-specific factors, a hypothesis that is
supported by analysis of the rat genome [21]. The rat
genome conserves genes that are involved in immunity,
metabolic
detoxification,
reproduction,
chemo-sensation, and human diseases [22, 23]. Increasing evidence indicates that rats recapitulate human diseases more accurately than mice. To increase
the diversity of animal models for human diseases, it
is compelling to expand the availability of genetically
manipulated rats.
To model human diseases in animals, inducible
mutations or overexpression of desired genes is necessary when the genetic manipulation causes embryonic or early postnatal lethality [24, 25]. As such,
multiple systems have been developed for conditional
gene manipulations. The Tet-off system has readily
been used in transgenic mice [26-29]. Compared to
thousands of transgenic mice reported, the availability of transgenic rats is limited to about 100 transgenic
lines characterized [1, 30-32]. As transgenic technology advances in rats [1, 2], the number of transgenic
rats is increasing at an accelerated speed [1, 33, 34]. To
express genes of interest in a conditional pattern in
rats, we developed transgenic rats carrying and expressing tetracycline-controlled transactivator (tTA)
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under the control of a ubiquitous promoter. The tTA
transgenic rats expressed the transgene tTA in many
tissues. The expression levels of the tTA transgene
were sufficient to vigorously and reversibly activate
reporter gene under control of the Tet-responsive
promoter. These tTA transgenic rat lines will be useful
in the conditional expression of human disease genes
in the rats.

2. Materials and Methods
Construction of transgenic DNA and creation of
transgenic rats
A Tet-off system was chosen to produce inducible and reversible gene expression in transgenic rats.
This system is readily used in transgenic mice [26-29].
The Tet-off system is comprised of two elements: a
tetracycline-controlled transactivator (tTA) and a
tTA-dependent promoter. The tTA-dependent promoter is a hybrid promoter that is constructed by
juxtaposing multiple tetracycline-responsive elements
(TRE) upstream of a minimal cytomegalovirus promoter (TREminiCMV). When a gene is placed under
control of the TREminiCMV promoter, transcription
of the gene depends on activation by the transcriptional activator tTA. The tTA activates its reporter
gene in the absence of tetracycline or tetracycline derivatives such as Dox (Dox), but is inactivated in the
presence of Dox. For robust gene expression, a strong
hybrid promoter, CAG (cytomegalovirus enhancer
fused to chicken beta actin promoter), was used to
drive a tTA gene that was extracted from the vector
pTet-off (Clontech) [35, 36]. The transgenic construct
CAG-tTA consisted of the CAG promoter, the noncoding exon along with the first intron of the beta
actin gene, tTA cDNA, and three repeats of the SV40
polyadenylation signal (Figure 1A). The human Leucine Rich Repeat Kinase 2 (LRRK2) gene tagged with
hemaglutinin (HA) was driven by the TRE promoter
and used as the reporter gene for tTA (Figure 2A).
Both the CAGtTA and the TREhLRRK2-HA
transgenic constructs were linearized by restriction
digestion and purified from an agarose gel. The
transgene DNA was injected into the pronucleus of
fertilized single-cell embryos of Sprague-Dawley (SD)
rats. Surviving eggs were transferred into pseudopregnant female rats. Transgenic founder rats were
identified by PCR-magnifying part of the transgenes
with
the
following
primers:
5’-AGCCTCTGCTAACCATGTTC-3’ (forward) and
5’-AACCTTCGATTCCGACCTCA-3’ (reverse) for the
tTA
transgene,
and
5’-CTGTTGATCGTCTTGGACTC-3’ (forward) and
5’-CCCAATCATTTCCAACATCC-3’ (reverse) for the

http://www.biolsci.org
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report gene hLRRK2. Copy number of the transgenes
was determined by quantitative PCR. Transgenes
were maintained on the genomic background of SD
rats. Each line of the tTA transgenic founders was
crossed with an expressing line of the hLRRK2-HA
transgenic rats to produce double transgenic offspring
(F1), in which the transcriptional activity of tTA was
examined. Animal use followed NIH guidelines. The
animal use protocol was approved by the Institutional
Animal Care and Use Committees (IACUC) at Thomas Jefferson University.

Doxycycline treatment
To suppress tTA-activated gene expression,
doxycycline hydrochloride (Dox; a Sigma-Aldrich)
was continually supplied in drinking water at desired
concentrations. Dox-containing water was supplied in
a light-protected bottle and was renewed every three
days. Rats were given regular food and water supplied with or without Dox of the indicated concentrations.

Quantitative PCR
Copy number of the transgene was estimated by
quantitative PCR. Genomic DNA was extracted from
tail biopsy and was adjusted to a constant concentration of 100 ng/μl. A pair of primers was selected specifically
for
the
tTA
transgene:
5’-AGCCTCTGCTAACCATGTTC-3’ (forward) and
5’-AACCTTCGATTCCGACCTCA-3’ (reverse). In
parallel, the rat tyrosine hydroxylase (TH; a known
single-copy gene) gene was used as an internal control
for PCR quantification and was magnified with the
primers 5’-CTCAAGAATCCTGTCACCAG-3’ (forward) and 5’-ACTGCCTTTCAGGGTATGTC-3’ (reverse). Rat genomic DNA was estimated to contain 3 x
109 base-pairs. The tTA transgene DNA was dissolved
in genomic DNA of nontransgenic rats to obtain a
series of standards from one to ten copies per genome.
The resulting standard curve of tTA gene copy number was used for estimation of tTA transgene copy
number in individual transgenic lines.
The mRNA level of the reporter gene human
LRRK2 was also estimated with quantitative PCR.
Total RNA was isolated from rat tissue with Trizol
reagent (Sigma) and was further purified by digesting
genomic DNA on a column (RNA easy kit and
RNase-free DNase: Qiagen). One microgram of the
purified RNA from each sample was reversely transcribed to cDNA with oligo-dT primer (RT kit, Invitrogen). Relative levels of hLRRK2 mRNA in individual samples were estimated by quantitative PCR
with
the
following
gene-specific
primers:
5’-CAGCCTGACTATCAACTTCT-3’ (forward) and
5’-TTGTTTGTGGATCGCTGTGA-3’ (reverse) for the
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reporter
gene
hLRRK2,
and
5’-TGGTTCGCTACTCCCTTGAC-3’ (forward) and
5’-CTTGATGGCCTGGGCAGTT-3’ (reverse) for rat
L17 gene. The mRNA level of the L17 gene was used
as an internal control for PCR quantification.
For quantitative PCR, the gene-specific primers
were used at a concentration of 500 nM. Gene doses
were measured by quantitative PCR with SYBR green
kit per manufacturer’s instruction (Qiagen). Cycling
conditions were 15 min at 95°C followed by 40 cycles
of 15 seconds at 94°C, 30 seconds at 60°C, and 20
seconds at 72°C. Aliquots of the amplified products
were separated on 3% agarose gels to ensure amplification of the specific products at the predicted length.
The threshold cycle number (Ct) for an examined
gene was normalized to the Ct for the individual internal genes: TH gene for estimation of tTA transgene
copy and L17 gene for estimation of reporter gene
mRNA. The relative mRNA level of the reporter gene
hLRRK2 was determined and expressed as a ratio of
the mRNA level in the Dox-treated rats to that in the
Dox-untreated rats, as described previously [37].

Western blotting
Animal tissues were homogenized in phosphate
buffer (pH 7.4) supplied with protease inhibitors
(Sigma). Tissue debris, unbroken cells, and cell nuclei
were removed by centrifugation at 16,000 × g for 10
minutes. Protein content in the cleared lysate was
determined by BCA assay (BioRad). Since protein
product of the reporter gene human LRRK2 was
about 280 kDa, the LRRK2 protein was barely detected in completely denatured sample [38]. Protein
sample of certain amounts was mixed with 2%
SDS-containing loading dye and was partially denatured by incubating at 60°C for 5 minutes. Proteins
were separated on 4-20% gradient SDS-PAGE and
blotted onto GeneScreen Plus membrane (Perkin
Elmer). Immunoreactivity to the epitope HA was detected by incubating the membrane with rabbit polyclonal antibody to HA (Rockland Inc., Pennsylvania).
Immunoreactivity to GAPDH was also detected by
incubating the membrane with a mouse monoclonal
antibody to GAPDH (Abcam) and used as a control
for equal loading. The immunoreactivity signal was
developed with Super Signal kit (Pierce).

Immunohistochemistry
Rats were transcardially perfused with 4% paraformaldehyde in 0.1 M ice-cooled phosphate buffer.
Their brains were dissected and further fixed in the
same fixative for additional 24 hours. The dissected
tissues were dehydrated in 30% sucrose and cut into
serial coronal sections (30 μm thick) on a Cryostat. For
detection of human LRRK2 protein, brain sections
http://www.biolsci.org
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were incubated sequentially with a rabbit polyclonal
antibody to the epitope HA (1:200; Rockland), with
biotinylated goat anti-rabbit IgG (1:500; Vector Laboratories),
and
with
peroxidase-conjugated
avidin-biotin complex (ABC kit; Vector Laboratories).
After thorough washing, bound antibodies were
visualized by addition of diaminobenzidine (Vector
Laboratories). Immunostained cells were observed
under a Nikon microscope and were documented
with a Nikon digital camera.
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genomes of the lines 5 and 11 because the copy number of the CAGtTA transgene was constant across
generations. In addition, we tried to breed tTA transgenic lines to obtain homozygotes and succeeded
with line 5 but not with line 11 (0 homozygotes in 30
transgenic offspring). No difference was observed in
gross health between the homozygote and the hemizygote tTA rats.

Rotarod test
Rats were first trained to stay on the rod of a rotarod (Med Associates) at a constant speed of 5 rpm,
once a day for 5 days. Following the training, rats
were tested on the Rotarod with an accelerating speed
of 0.2 rpm/s, starting at 5 rpm. During a testing day,
each rat was given three successive trials with a
20-minute interval. The latency to fall from the rod
was recorded for each trial. The average latency was
calculated for each testing day.

Statistical analysis
Data are expressed as means + SD. The statistical
significance was tested with analysis of variance
(ANOVA) followed by Tukey’s post hoc test to compare group means. In all analyses, the null hypothesis
was rejected at a level of 0.05.

3. Results
Copy-related expression of the tTA transgene in
CAG-tTA transgenic rats
Production of transgenic rats appears more difficult than creation of transgenic mice because the
pronuclei of rat zygotes are less regular and less uniform than those of mouse zygotes. Furthermore, the
plasma and pronuclear membranes of rat zygotes are
more plastic and sticky than those of mouse zygotes.
About 31–75% of rat zygotes are viable after microinjection and are ready for implantation into pseudopregnant females [2, 30]. We injected 540 single-cell
embryos of SD rats with the CAGtTA transgene DNA
at a concentration of 2ng/µl (microinjection buffer:
Invitrogen) and transplanted 386 viable embryos into
12 pseudopregnant SD female rats (Figure 1A). From
68 pups, we identified three founder rats carrying the
CAGtTA transgene (Figure 1B). Two of the three
transgenic founders transmitted the transgene (Figure
1B: lines 5 and 11); however, founder 4 was infertile.
We determined the copy number of the transgene in
individual lines by quantitative PCR and detected 2
copies of the CAGtTA transgene in the line 5, 8 copies
in the line 11, and 25 copies in the founder 4. The
transgene was integrated at a single location in the

Figure 1. Widespread expression of the tTA
transgene in tTA transgenic rats. A, Schematic shows
the structure of the tTA transgene. Two pairs of primers
were designed for regular PCR to determine the genotypes
of transgenic rats (P2 + P3) or for reverse-transcriptional
PCR (RT-PCR) to detect expression of the transgene tTA
(P1 + P3). B, Results of representative PCR with the
primers P2 and P3 show three founder rats (lines 4, 5, and
11). C+, nontransgenic rat DNA mixed with the transgene
tTA; C-, nontransgenic rat DNA. C, RT-PCR with primers
P1 and P3 detected a wide expression of the transgene tTA
in various tissues: OB, olfactory bulb; hippo, hippocampus;
CB, cerebellum; BS, brainstem; SC, spinal cord; SM, skeletal
muscle; and other tissues as indicated. RT-PCR for the rat
L17 gene serves as an internal control for equal loading of
cDNA pools. RT-PCR was run for 25 cycles to show the
difference in transgene expression between the two expressing lines. D, Western blotting showed that expression

http://www.biolsci.org
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of the tTA transgene was not detected at protein level in
the two transmittable lines. C+, HEK293 cells were transiently transfected with the tTA transgene construct and
the cell lysate was used as the positive control.
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ous findings in transgenic mice [26, 39], our results
suggest that limited levels of tTA transgene expression were sufficient to vigorously activate its reporter
gene in vivo.

To detect transgene expression, we first tried
immunoblotting with commercially available antibodies that were raised with peptides corresponding
to the tTA protein. Unfortunately, we could not detect
tTA protein by western blotting in the two transmittable lines (Figure 1). In previous studies, low expression of tTA transgene has been shown sufficient to
vigorously activate a tTA-dependent reporter gene
[26, 39]. We designed a pair of primers spanning the
intron of tTA transgene, and thus, we could identify
mature tTA mRNA by RT-PCR (Figure 1A). We detected expression of the tTA transgene in various tissues of the two transmittable lines (Figure 1C). In
many tissues, the tTA transgene was expressed at
higher levels in the 8-copy line (line-11) than in the
2-copy line (line-5), suggesting a pattern of transgene
copy-related expression.

Vigorous activation of tTA-dependent reporter
gene in the double transgenic rats
To test whether limited levels of tTA gene expression were sufficient to activate its target genes in
vivo, we crossed the tTA transgenic lines with a
tTA-responsive reporter line that carried human
LRRK2 gene under control of the TREminiCMV
promoter (Figure 2A). By RT-PCR, we detected a
widespread expression of the reporter gene in many
tissues examined (Figure 2B). Since the reporter gene
was tagged by hemaglutinin (HA), expression of the
reporter gene could be detected by immunoblotting or
immunohistochemistry for HA antigen. HA immunoreactivity was detected only when both the tTA and
the reporter genes were presented in the transgenic
rats, but was not detected when only the reporter
transgene was present (Figure 2C). These results indicate that expression of the reporter gene depended
on tTA activation and that leakage of the reporter
gene was negligible. Further, western blotting detected strong HA immunoreactivity in the double
transgenic rats carrying the 8-copy tTA transgene, but
detected relatively weak HA immunoreactivity in the
rats carrying 2-copy tTA transgene (Figure 2C). Expression levels of the reporter gene corresponded
with those of the tTA transgene. In addition, immunohistochemistry with an HA antibody detected
widespread expression of the reporter gene in many
tissues of double-transgenic animals, but no expression in tissues of animals carrying the reporter transgene alone (Figure 2D-G). Consistent with the previ-

Figure 2. A reporter gene driven by a
tTA-dependent promoter is transcriptionally activated by tTA and robustly expressed in various
tissues. A, Schematic shows the structure of the reporter
gene for probing tTA transcriptional activity. The human
LRRK2 gene (hLRRK2), tagged by hemaglutinin (HA), was
driven by a hybrid promoter comprising a minimal CMV
promoter of 110 bp and seven repeats of tetracycline-responsive elements. The noncoding exon 1 and the
first intron of human ubiquitin C gene were placed between
the hybrid promoter and the human LRRK2 gene to enhance gene expression. A pair of primers (P1, P2) was
designed to magnify the mature cDNA of the transgene,
giving a band of 240 base-pairs. B, Representative RT-PCR
shows that the reporter gene was widely expressed in
various tissues of a double transgenic rat carrying both the

http://www.biolsci.org
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CAGtTA and the TREhLRRK2 transgenes. Genomic
DNA-eliminated cDNA pools were extracted from the
following tissues: 1, olfactory bulb; 2, cortex; 3, striatum; 4,
hippocampus; 5, cerebellum; 6, brainstem; 7, spinal cord; 8,
skeletal muscle; 9, heart; 10, lung; 11, liver; 12, spleen; 13,
kidney; 14, stomach; 15, intestine; 16, colon; 17, testis; 18,
ovary; 19, skin. RT-PCR for rat L17 gene serves as an internal control for equal loading of cDNA pools. C, Western
blot detected widespread expression of the reporter gene
hLRRK2 upon activation by the tTA transgene in transgenic
lines 5 or 11. D-G, Immunoreactivity to HA tag is detected
only in the tissues of the CAGtTA/TREhLRRK2-HA double
transgenic rat (E, G), not in the tissues (D, F) of nontransgenic rats (WT).

Suppression of tTA-activated gene expression by
Dox
One advantage of the tetracycline-regulatory
system is that transgene expression can be suppressed
temporally. To test whether the tTA-activated gene
was responsive to Dox, we first treated adult rats
carrying both the tTA and the reporter transgenes.
When administered at a constant concentration in
drinking water, Dox effectively suppressed expression of the tTA-dependent reporter gene and reached
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its maximal effect in a dose-dependent pattern (Figure
3A, B). By day 5, Dox administered at 500 μg/ml reduced mRNA and protein levels of the reporter gene
below detection threshold. In contrast, lower doses of
Dox took a longer time to reach its maximal effects:
100 μg/ml and 20 μg/ml of Dox reached the maximal
effect by day 7 and by day 10, respectively. To improve drug efficiency, we tested a complex regime of
Dox administration: Dox administered at 500 μg/ml
for 2 days and then at 20 μg/ml for the remainder of
the experiment. The complex (Cp) regime reached
maximal effect by day 5 and achieved a comparable
result to the highest dosage for Dox (Figure 3A, B).
To study the functions of embryo-lethal genes in
adult animals, we should avoid expression of genes at
the embryonic and postnatal stages. Therefore, we
tested
the
gene-suppression
efficiency
of
milk-secreted Dox in postnatal rats. Expression of the
reporter gene was effectively suppressed in postnatal
rats from 2 days of age through weaning when their
mother was given Dox (20 μg/ml) in drinking water
since the date of mating (Figure 3C, D). Our results
show that expression of the tTA-dependent transgene
was subject to a tight and constant suppression by
Dox in both adult and postnatal rats.

Figure 3. Dox-dependent suppression of tTA-activated gene expression in transgenic rats. A, Dox turned off a
tTA-dependent report gene at a dose-dependent speed. Adult female rats doubly transgenic for CAGtTA (line 11) and
TREhLRRK2 were given Dox in drinking water at the indicated concentrations (Cp: 500 μg/ml for 2 days and then 20 μg/ml
for the duration of the experiment). At the indicated time (d: day) after Dox treatment, rats were sacrificed for tissue
collection. The mRNA levels of the report gene were measured by quantitative RT-PCR and expressed as a percentage of
levels in the Dox-untreated rats. Data are means + SD (n = 3). B, Consistent with the RT-PCR results shown in A, western
blot detected no expression of the reporter gene in the forebrain after Dox was administered for certain time (d: day). Brain
http://www.biolsci.org
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tissues were taken from the same rats used for the RT-PCR shown in A. Immunoreactivity to GAPDH was also measured
as a control for equal loading. C, Milk-secreted Dox continually suppressed tTA-dependent gene expression in neonatal rats.
Pregnant rats were given Dox (20 μg/ml) in drinking water from the time of mating onward. The pups were sacrificed at
indicated ages (d: day). Their forebrain was removed from the skull and dissected for extraction of RNA and protein. The
mRNA levels of the reporter gene were measured by quantitative RT-PCR and expressed as a percentage of levels in the
Dox-untreated rats. Data are means + SD (n = 4). Protein levels of the reporter gene were measured by western blot (D).
For detection of HA-tagged human LRRK2 protein, 50 µg of total protein from each sample was loaded.

Reversibility of tTA-dependent gene expression
after Dox withdrawal
Compared to other gene regulatory systems,
such as the Cre-lox system, a big advantage of the Tet
regulatory system is that gene suppression can be
released by Dox withdrawal. We first tested gene
restoration in adult rats that were treated with Dox for
20 days. Expression of the reporter gene was efficiently restored in all the rats treated with three regimes of Dox (Figure 4A, B). Sixty days were required
to remove the remnant effect of Dox administered at
500 μg/ml, but only 40 days were required to eliminate the remnant effect of Dox administered at 20

μg/ml (Figure 4A, B). Restoration time of gene expression is inversely relative to the dosage of Dox
administered. We then tested recovery of gene expression in the rats inherently treated with Dox. We
observed that gene recovery time depended on the
age at Dox withdrawal. Periods of 40, 60, and 90 days
were needed to recover gene expression in the rats
depleted of Dox at ages of 15, 30, and 60 days, respectively (Figure 4C, D). Rats grow faster at early ages
than at later ages (Figure 5A). Early withdrawal of
Dox may require less time to remove the remnant
effect of Dox due to a dilution effect from physical
body expansion.

Figure 4. Restoration of tTA-dependent gene expression depends on the dosage of Dox administered. A, B:
Residual effect of Dox temporally administered depends on the dose of Dox. Female rats at age 40 days were given Dox in
drinking water at indicated concentrations (Cp: 500 μg/ml for 2 days and then 20 μg/ml for the rest time) for 20 consecutive
days. Rats were sacrificed at indicated days (d: day) after Dox withdrawal. Restoration of gene expression in the forebrain
was examined by quantitative RT-PCR for human LRRK2 mRNA (A) and by western blotting for HA immunoreactivity (B).
C, D: Residual effects of Dox depend on the duration of Dox administration. Mating rats were given Dox in drinking water
at 20 μg/ml. Dox was withdrawn (WD: withdrawal) at the indicated ages of newborn rats. Forebrains of neonates were
dissected at the indicated times after Dox withdrawal. Expression of the reporter gene was examined by quantitative
RT-PCR for human LRRK2 mRNA (C) and by western blotting for HA immunoreactivity (D). Immunoreactivity to GAPDH
served as a control for equal loading (50 μg of total protein per lane). Data are means + SD (n = 3-4).

http://www.biolsci.org
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(Figure 5B). Insertion and expression of the tTA
transgene did not affect the growth or psychomotor
function of rats.

4. Discussion

Figure 5. The tTA transgene does not affect rat
growth or psychomotor function. A, The body weight
of each rat was measured weekly after genotypes were
determined. B, Psychomotor function of male rats was
tested with a Rotarod weekly after a 5-day training period.
Performance on the Rotarod was not different between the
tTA transgenic rats and their nontransgenic littermates.
Data are means + SD (n = 5-8).

No effect of the tTA transgene on animal growth
or motor function
In transgenic studies, gene insertion may cause
unwanted phenotypes due to interruption of other
genes at the insertion site. In addition, overexpression
of the transcriptional factor tTA may cause side effects
[39]. We examined tTA transgenic rats for overall
health, but failed to observe any abnormal phenotypes. No differences were observed in the size of
liver, heart, kidney, and brain between the tTA
transgenic and the nontransgenic rats (data not
shown). Compared to nontransgenic littermates, the
tTA transgenic rats gained body weight at comparable
speeds during postnatal development (Figure 5A). We
monitored motor function using Rotarod test and
observed no difference in psychomotor function between tTA transgenic and nontransgenic littermates

To develop a transgenic line for conditional expression of desired genes in rats, we used the tetracycline regulatory system and generated several lines of
the transgenic rats carrying the tTA transgene. Using
a vigorous and ubiquitous promoter to drive the tTA
transgene, we obtained widespread expression of tTA
in the central nerve system, skeletal muscle, heart,
lung, and in most abdominal organs. Expression of
the tTA was sufficient to vigorously activate its reporter gene, but was below the threshold to produce
toxicity to the rats. These tTA transgenic rats are a
model of inducible and reversible gene expression in
the rat, and could be valuable to the development of
genetic rat models for human diseases.
The Tet-regulatory system is widely used to
achieve inducible and reversible expression of desired
genes in vivo. To date, a great number of transgenic
mice have been generated to express tTA (Tet-off) or
rtTA (Tet-on) transactivators in ubiquitous or tissue-specific patterns [26, 27, 39]. While few lines of
transgenic rats have been created to express tTA in
cell-specific patterns [29, 40, 41], a single line of tTA or
rtTA transgenic rat is not available for ubiquitous
activation of reporter gene in various cell types. To
obtain ubiquitous expression of the tTA transgene in
rats, we chose the ubiquitous promoter CAG, a hybrid
promoter that has been constructed by fusing the cytomegalovirus enhancer with the chicken beta actin
promoter. CAG has been shown to produce ubiquitous and robust gene expression in transgenic mice
[35, 42, 43]. Although CAG is a vigorous promoter,
expression of tTA protein was not detectable by immunoblotting in the two transmittable lines (data not
shown). We used the original bacterial codon for tTA.
Sanbe et al. reported that bacterial codon usage bias
leads to alternative splicing of tTA mRNA and results
in a low abundance of full-length tTA mRNA [39]. As
a transcriptional activator, tTA at limited levels
should be sufficient to activate its target gene. Excessive expression of tTA protein may cause toxicity to
the cells because high abundance of exogenous
transactivator may interfere with cellular transcription activity.
Indeed, enhanced expression of tTA using
mammalian codon causes toxicity in transgenic mice
[39, 44]. To balance ubiquitous with adequate gene
expression, we chose a ubiquitous promoter as the
driver, but used the original bacterial codon for tTA.
Consistent with previous finding in transgenic mice
http://www.biolsci.org
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[26, 35, 39, 42, 43], our results in transgenic rats demonstrated that expression of tTA with bacterial codon
was under the detection threshold by western blotting, but was sufficient to vigorously activate its target
gene in various tissues. Insertion or expression of the
tTA transgene may interfere with endogenous genes
and cause toxicity to the animals. If the toxicity of the
tTA transgene is evident, the toxicity should be reflected as an effect on growth, overall health, or organ
development. In the two transmittable lines of transgenic tTA rats, no detectable abnormality was observed. These results suggest that insertion of the tTA
transgene did not result in a deleterious dominant
mutation and that expression of the tTA transgene did
not obviously interfere with endogenous genes. These
transgenic rats express tTA within a safe dosage and
at sufficient levels to activate the target gene.
The dynamics of Dox-regulated gene expression
were thoroughly examined for the first time in transgenic rats. We not only examined suppression of
tTA-activated gene expression by Dox, but also examined reversibility of tTA-dependent gene expression after Dox withdrawal. Both the suppression and
the reversal of gene expression were tested in adult
and neonatal rats. In the two transmittable lines,
tTA-mediated activation of the reporter gene was
fully subjected to the regulation by Dox. In transgenic
mice,
Dox
dose-dependently
suppresses
tTA-activated gene expression and washout of Dox
remnant effect also corresponds to Dox dosage used
[26, 39]. Similarly, Dox reached its maximal effect of
gene suppression at speeds proportional to its dose.
High dose of Dox (500 μg/ml in drinking water) took
a short time to fully suppress tTA-activated gene expression, but required a much long time to remove its
remnant effect. In our studies, a duration of 5 days
appeared to be the minimal time for complete gene
suppression by orally administered Dox. We tested a
complex regime of Dox administration to quickly
reach the maximal effect but to successfully avoid
extended duration of Dox cleanout. Dox was used at a
high dose (500 μg/ml in drinking water) for 2 days to
reach its effective concentration quickly and then used
at a low dose (20 μg/ml) to maintain its effect constantly. This improved regime of Dox administration
can help achieve a quick switch of tTA-activated gene
expression between ON and OFF status. In addition,
parental administration of Dox fully suppressed
tTA-activated gene expression in offspring rats.
Milk-secreted Dox was sufficient to reach its effective
concentration in neonatal rats. Parental administration of Dox can help provide a constant suppression
of tTA-dependent gene expression during embryonic
and postnatal development. We also tested the tTA
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transgenic lines with another reporter gene and observed similar results (data not shown).
Although laboratory mice are preferred for functional genetics, laboratory rats show significant advantages as model animals in pharmacological and
toxicological studies, in behavioral analysis, in microsurgery such as cell transplantation, and in studies
on neurological diseases. In modeling some human
diseases, animal species may play an important role in
phenotypic expression. For example, no substantial
loss of dopaminergic neurons is observed in human
alpha-synuclein transgenic mice [45, 46], but progressive loss of the neurons is induced by transient expression of human alpha-synuclein in rats [47]. Animal species may not be a sole factor contributing to
the variation of phenotypic expression in alpha-synuclein models. In some genetic models for
human disease, developmental compensation may
dilute phenotypic expression when the gene is constitutively mutated. Such compensatory changes are
increasingly observed in genetic models [48, 49].
Disrupting one gene of the JNK family causes compensatory changes in the other related genes [49].
Studies on Jnk2 knockout mice with the gene disrupted from germline suggest a negative regulatory
role in cell proliferation for the protein kinase Jnk2
[50]. In contrast, studies of Jnk2 inhibition in adult
mice suggest Jnk2 as a positive regulator for cell proliferation [49]. These distinct phenotypes may result
from developmental compensation by upregulated
expression of the related genes [49]. Compared with
the human, the rodent has a short lifetime. Developmental compensation may buffer the detrimental effects of gene mutation and thus attenuate or even
prevent the phenotypes of gene mutation from developing in a rodent’s lifetime. Selective expression of
disease genes in adult animal may increase the chance
to reproduce the phenotypes of human diseases in the
animals. Recent advances in transgenic RNAi indicates that RNAi-mediated gene silencing can reproduce phenotypes of the gene knockout [37, 51, 52].
Transgenic RNAi is a convenient approach to achieve
hypomorphic phenotypes in the transgenic rats. To
maintain RNAi transgenic lines, conditional expression of the RNAi transgene is necessary when the
hypomorphic phenotype is lethal or infertile. In the
aforementioned applications, the tTA transgenic rats
would be a valuable tool for accomplishment of these
goals.
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